|Model input parameters|
|Category||Definition||Value||Base-case value||Range of values in sensitivity analysis||Source|
|CKRT demand during the initial wave of the COVID-19 pandemic||IHME model update (Choose Date of Data)||IHME projections from 06/10||06/10/2020||04/22/2020, 06/10/2020||IHME COVID-19 estimate downloads|
|CKRT demand during the initial wave of the COVID-19 pandemic||Incidence of AKI 3D requiring CKRT among hospitalized patients with COVID-19 (%)||5.20%||5.20%||4.8 - 6.9%||1. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-2059.|
2. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and Clinical Course of 1000 Patients with Coronavirus Disease 2019 in New York: Retrospective Case Series. BMJ. 2020;369:m1996.
3. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, Clinical Course, and Outcomes of Critically Ill Adults with COVID-19 in New York City: A Prospective Cohort Study. Lancet. 2020;395(10239):1763-1770.
4. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372-2374.
5. Hirsch JS, Ng JH, Ross DW, et al. Acute Kidney Injury in Patients Hospitalized with COVID-19. Kidney Int. 2020;98(1):209-218.
|CKRT demand during the initial wave of the COVID-19 pandemic||Time from hospitalization to AKI 3D requiring CKRT among hospitalized patients with COVID-19 (days)||7 days||7 days||5 - 10 days||1. Zhou F, Yu T, Du R, et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet. 2020;395(10229):1054-1062.|
|CKRT demand during the initial wave of the COVID-19 pandemic||Duration of CKRT among hospitalized patients with COVID-19 (days)||6 days||6 days||6 - 9 days||1. Palevsky PM, Zhang JH, O'Connor TZ, et al. Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury. N Engl J Med. 2008;359(1):7-20.|
2. Hirsch JS, Ng JH, Ross DW, et al. Acute Kidney Injury in Patients Hospitalized with COVID-19. Kidney Int. 2020;98(1):209-218.
|CKRT demand during the initial wave of the COVID-19 pandemic||Non-COVID-19 CKRT demand multiplier during the COVID-19 pandemic||0.40||0.40||0.25 - 0.75||1. Harvard Global Health Institute COVID-19 model. https://docs.google.com/spreadsheets/d/1XUVyZF3X_4m72ztFnXZFvDKn5Yys1aKgu2Zmefd7wVo/edit#gid=1576394115. Accessed July 6, 2020.|
2. American Hospital Association, AHA Hospital Statistics, Chicago, IL. American Hospital Association 2018.
3. American Hospital Directory. Hospital Statistics by State. https://www.ahd.com/state_statistics.html. Accessed July 6, 2020.
|CKRT demand during the initial wave of the COVID-19 pandemic and CKRT capacity||Prevalence of AKI 3D among ICU patients pre-COVID-19 (%)||8.8%||8.80%||6.6 - 11.0%||1. Melo FAF, Macedo E, Fonseca Bezerra AC, et al. A Systematic Review and Meta-analysis of Acute Kidney Injury in the Intensive Care Units of Developed and Developing Countries. PLoS One. 2020;15(1):e0226325.|
|CKRT capacity||CKRT capacity multiplier||1.50 capacity multiplier||1.50||1.25 - 1.75||Estimates based on clinical experience informed by local capacity.|
|Nationwide CKRT Capacity||7,032|
|Nationwide CKRT demand at peak resource utilization during the COVID-19 pandemic||4,985 (4,582 - 6,105)|
Nationwide CKRT machine shortage at peak resource utilization during the COVID-19 pandemic
|1,088 (910 - 1,568)|
|Number of states projected to encounter CKRT shortages||6|
|List of states projected to encounter CKRT shortages||CT, MD, MA, MI, NJ, NY,|
|Number of states projected to encounter possible CKRT shortages||8|
|List of states projected to encounter possible CKRT shortages||AZ, CO, LA, NE, NM, RI, SC, WY,|